| 0.88 -0.02 (-2.22%) | 04-25 15:22 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.28 | 1-year : | 1.56 |
| Resists | First : | 1.1 | Second : | 1.34 |
| Pivot price | 0.95 |
|||
| Supports | First : | 0.71 | Second : | 0.59 |
| MAs | MA(5) : | 0.93 |
MA(20) : | 0.94 |
| MA(100) : | 0.79  |
MA(250) : | 1.1 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 32 |
D(3) : | 44.9 |
| RSI | RSI(14): 47.1 |
|||
| 52-week | High : | 4.34 | Low : | 0.56 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ YCBD ] has closed above bottom band by 9.7%. Bollinger Bands are 20.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.95 - 0.96 | 0.96 - 0.96 |
| Low: | 0.86 - 0.86 | 0.86 - 0.87 |
| Close: | 0.89 - 0.9 | 0.9 - 0.91 |
cbdMD, Inc. produces and distributes various cannabidiol (CBD) products. The company owns and operates consumer hemp-based CBD brands, such as cbdMD, Paw CBD, and cbdMD Botanicals. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, bath bombs, bath salts, and sleep aids. It also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name. The company distributes its products through its e-commerce Website, third-party e-commerce sites, wholesalers, and various brick and mortar retailers in the United States. It has a research partnership with the University of Mississippi to identify novel cannabinoids. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. was incorporated in 2015 and is headquartered in Charlotte, North Carolina.
Tue, 09 Apr 2024
Former CBD CEO, SEC reach agreement over deals that falsely boosted company's value - HempToday
Tue, 02 Apr 2024
cbdMD Announces Executive Changes and Shareholder Vote Outcomes - TipRanks.com - TipRanks
Mon, 05 Feb 2024
Medical Cannabis Pioneer cbdMD Secures $1.2M To Fund Rollout Of Functional Mushroom Products - cbdMD (AME - Benzinga
Sat, 03 Feb 2024
cbdMD Secures $1.25M Through Convertible Note Agreement - TipRanks.com - TipRanks
Fri, 02 Feb 2024
cbdMD Announces Financing of $1,250,000 - Yahoo Finance
Wed, 27 Dec 2023
YCBD Stock Earnings: cbdMD Reported Results for Q4 2023 - InvestorPlace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 3 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 17.9 (%) |
| Held by Institutions | 6 (%) |
| Shares Short | 267 (K) |
| Shares Short P.Month | 296 (K) |
| EPS | -15.65 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.01 |
| Profit Margin | -82.5 % |
| Operating Margin | -29.8 % |
| Return on Assets (ttm) | -13 % |
| Return on Equity (ttm) | -60 % |
| Qtrly Rev. Growth | -28.8 % |
| Gross Profit (p.s.) | 7.81 |
| Sales Per Share | 9.19 |
| EBITDA (p.s.) | -2.73 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.06 |
| PEG Ratio | 0 |
| Price to Book value | 0.09 |
| Price to Sales | 0.09 |
| Price to Cash Flow | -0.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|